Skip to main content

Table 2 Frequency of use of immunosuppressive agents during the study

From: Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

Immunosuppressive drugs

Placebo (n = 13)

Belimumab

  

1.0 mg/kg (n = 15)

4.0 mg/kg (n = 14)

10 mg/kg (n = 14)

20 mg/kg (n = 14)

All active (n = 57)

Prednisone

9 (69)

14 (93)

9 (54)

10 (71)

8 (57)

41 (72)

Methotrexate

2 (15)

1 (7)

0

2 (14)

3 (21)

6 (11)

Azathioprine

5 (38)

2 (13)

2 (13)

2 (14)

1 (7)

7 (12)

Mycophenolate

0

1 (7)

1 (7)

1 (7)

5 (36)

8 (14)

None

3 (23)

1 (7)

5 (36)

3 (21)

3 (21)

12 (21)